Preclinical models have demonstrated superior therapeutic efficacy of intraventricular injection of CAR-T cells targeting HER2 (ref. 61) and IL13Ra2 (ref. 62) in breast cancer brain metastases and in glioblastoma. This evidence concerns the gene ERBB2 and breast carcinoma.